Shareholder’s corner

 


* Source : EURONEXT(1)
The BIOCORP share price which is displayed in real-time is provided exclusively for information and not for trading purposes. Before any transaction, please contact your broker. BIOCORP cannot be held responsible for inaccurate, delayed or interrupted data, regarding the share price announced on its website.

* Source : EURONEXT
The BIOCORP share price which is displayed in real-time is provided exclusively for information and not for trading purposes. Before any transaction, please contact your broker. BIOCORP cannot be held responsible for inaccurate, delayed or interrupted data, regarding the share price announced on its website.

* Source : EURONEXT
The BIOCORP share price which is displayed in real-time is provided exclusively for information and not for trading purposes. Before any transaction, please contact your broker. BIOCORP cannot be held responsible for inaccurate, delayed or interrupted data, regarding the share price announced on its website.
BIOCORP 08/06/2023 17:35:03 CET
34.0 € Var. : 0 %
Bid / Offer 33.9 € / 34.0 €

Opening 33.9 €
Day high 34.0 €
Day low 33.9 €

Previous Close 33.9 €

Replay – Webinar – Biocorp’s future projects and outlook

https://youtu.be/38Iu0D_FIWo

 

Analysis by Portzamparc – since 2022

230329 Note_Biocorp_EN

230320 Note Biocorp EN

230123 Note_Biocorp_EN

221207 Note Biocorp

220929 Note_Biocorp

Portzamparc_Note_June_10_2022

Biocorp uses Sponsored Research Services provided by Portzamparc.The Financial Analyst tracking the value as of 2022/12/20 is Clement Bassat.

 

Analysis by Gilbert Dupont – since 2020

Gilbert Dupont Study December 7, 2022

Gilbert Dupont Study June 22, 2020

French versions:

Flash du 29 mars 2023

Flash du 5 avril 2022

Flash du 13 avril 2021

Note du 1er octobre – Extrait

Note du 22 juin 2020

Analysis by Bryan, Garnier & Co – since 2020

Bryan Garnier BIOCORP Dec 2022

Flash du 29 septembre 2022

Bryan Garnier_BIOCORP_Apr_2022

Bryan Garnier_BIOCORP_Apr_2021

Bryan Garnier_BIOCORP_Feb2021

Bryan Garnier_BIOCORP_April 2020

 

Annual results

230329 PR BIOCORP

220405 PR_BIOCORP

210927 Half_Year_Results

210408_Annual results

210927_Half year results 2021

 

The good reasons to become a shareholder of BIOCORP

  • Participate in improving the lifestyle of patients
  • Join a bold and agile R & D approach
  • Support the creation of value of a recognized player on its market
  • Support the development of major innovations in the MedTech sector

 

How to become a shareholder?

Managed bearer or registered shareholder: contact your financial intermediary to buy BIOCORP shares and register them on your securities or PEA account. Then you remain your preferred contact for the management of your share portfolio.

Registered shareholder: you can contact our registered share manager, CACEIS.

 

(1) This website contains data provided by Euronext. Such data is for information purposes only and is not a recommendation to engage in investment activities. Such data is provided “as is” without representation or warranty of any kind. Whilst all reasonable care has been taken to ensure the accuracy of the data, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on data provided. No Euronext data shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with such data shall vest in Euronext. No part of it may be redistributed or reproduced in any form without the prior written permission of Euronext. Euronext does not control the content of this website and does not guarantee the accuracy, integrity or quality of such content and under no circumstances will Euronext be liable in any way for such content. Euronext refers to Euronext N.V. and its affiliates.